Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
- Sponsor
- Seoul National University Hospital
- Study ID
- NCT02864472
- Phase
- PHASE4
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PDT — PROCEDUREPDT and ranibizumab
- Ranibizumab — DRUGRanibizumab
- ranibizumab PRN — DRUGranibizumab PRN
Study Details
The aim of this study is to compare the efficacy of early intervention of PDT combination compared with consecutive monthly treatment of intravitreal ranibizumab injections in PCV patients showing insufficient response with initial loading dose.
Key Dates
- First listed
- Aug 12, 2016
- Start date
- Sep 30, 2016
- Status verified
- Aug 2016
- Primary completion
- Jun 30, 2018
- Completion
- Jan 31, 2019
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
Arms
- Other: combination Txcombination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
- Other: mono TxRanibizumab (at 4 weeks interval) \*3 (M0-2) + ranibizumab PRN (M3-6)
Primary Outcome Measure
Change in central retinal thickness [ Time Frame: after 6month ]
Central Contacts
- Jangwon Heo, MD82-2-2072-2438
- Serang Choi, MD82-2-2072-2953
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- High Resolution Retinal ImagingRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationPHASE1 · Recruiting · Astellas Institute for Regenerative Medicine · Los Angeles, California